论文部分内容阅读
目的研究艾迪注射液联合二线化疗在晚期非小细胞肺癌治疗中的客观疗效。方法将46例非小细胞肺癌患者随机分为治疗组(25例)和对照组(21例)。治疗组采用艾迪注射液联合二线化疗,对照组单用化疗,方案与治疗组相仿。结果治疗组肿瘤缓解率和无进展生存期与对照组比较差异无统计学意义(P>0.05);但疾病控制率治疗组为68.0%,对照组为52.3%,两组比较有统计学意义(P<0.05);对照组的血液学毒性和消化道反应及感染较治疗组严重,其中白细胞下降及感染两组比较有统计学意义(P<0.05)。结论艾迪注射液提高二线化疗的疗效,减轻毒副反应,保护骨髓,减少感染机率,提高机体免疫力。
Objective To study the objective effect of Aidi injection combined with second-line chemotherapy in the treatment of advanced non-small cell lung cancer. Methods 46 patients with non-small cell lung cancer were randomly divided into treatment group (n = 25) and control group (n = 21). The treatment group with Aidi injection combined with second-line chemotherapy, the control group chemotherapy alone, the program and treatment group similar. Results There was no significant difference in tumor response rate and progression-free survival between treatment group and control group (P> 0.05). However, the disease control rate was 68.0% in treatment group and 52.3% in control group, with significant difference between the two groups P <0.05). The hematological toxicity, gastrointestinal reaction and infection in the control group were more serious than those in the treatment group. The leukopenia and infection in the two groups were statistically significant (P <0.05). Conclusion Aidi injection can improve the curative effect of the second-line chemotherapy, reduce the side effects, protect the bone marrow, reduce the infection rate and improve the body immunity.